Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2009

Cenix to Conduct RNAi-Based Target Discovery for Boehringer Ingelheim

  • Cenix BioScience will help Boehringer Ingelheim discover novel therapeutic drug targets. The firm will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in what will be a genome-scale screen using cultured human cells.

    Multiparametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement Boehringer Ingelheim’s assays to generate insights into the cellular functions and loss-of-function phenotypes of analyzed genes.

    Such RNAi datasets offer a highly predictive and cost-effective basis for mining the human genome to discover and prioritize targets for therapeutic drug development in a wide range of disease fields, according to Cenix.

    ---

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »